Goldman Sachs Group Inc. Sells 63,772 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Goldman Sachs Group Inc. cut its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 21.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 238,522 shares of the specialty pharmaceutical company's stock after selling 63,772 shares during the period. Goldman Sachs Group Inc. owned 0.38% of Jazz Pharmaceuticals worth $29,338,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Cape Investment Advisory Inc. boosted its position in Jazz Pharmaceuticals by 14,600.0% during the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company's stock worth $36,000 after purchasing an additional 292 shares during the period. Covestor Ltd boosted its position in Jazz Pharmaceuticals by 676.5% during the 3rd quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company's stock worth $51,000 after purchasing an additional 345 shares during the period. Assetmark Inc. boosted its position in Jazz Pharmaceuticals by 37.1% during the 4th quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company's stock worth $54,000 after purchasing an additional 119 shares during the period. Headinvest LLC purchased a new stake in Jazz Pharmaceuticals during the 3rd quarter worth $56,000. Finally, V Square Quantitative Management LLC boosted its position in Jazz Pharmaceuticals by 63.9% during the 4th quarter. V Square Quantitative Management LLC now owns 680 shares of the specialty pharmaceutical company's stock worth $84,000 after purchasing an additional 265 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Neena M. Patil sold 5,000 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the sale, the executive vice president now owns 36,629 shares in the company, valued at $4,016,369.85. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.40% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Up 1.7 %

Shares of Jazz Pharmaceuticals stock traded up $1.86 during trading on Monday, reaching $109.83. The company had a trading volume of 834,335 shares, compared to its average volume of 696,918. The company has a market cap of $6.93 billion, a price-to-earnings ratio of 22.65, a price-to-earnings-growth ratio of 1.65 and a beta of 0.62. The firm's fifty day moving average is $109.06 and its 200-day moving average is $117.10. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. Jazz Pharmaceuticals plc has a fifty-two week low of $103.01 and a fifty-two week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing the consensus estimate of $3.53 by ($1.55). The business had revenue of $901.98 million for the quarter, compared to analyst estimates of $938.99 million. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. On average, analysts anticipate that Jazz Pharmaceuticals plc will post 15.35 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. upped their price target on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, March 22nd. Royal Bank of Canada reiterated an "outperform" rating and issued a $195.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $180.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. StockNews.com lowered shares of Jazz Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Wednesday, June 19th. Finally, UBS Group cut their price objective on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a "neutral" rating on the stock in a report on Friday, March 1st. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $190.00.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.